Safety And Efficacy Of Sunitinib In An Expanded-Access Trial Of Metastatic Renal Cell Carcinoma (mRCC)

April 13th, 2008 | Category: Cancer

UroToday.com - Sunitinib malate is an oral, multi-targeted tyrosine kinase inhibitor with direct anti-tumor and anti-angiogenic activities, internationally approved for the first-line treatment of advanced RCC. that universal, open-label trial was undertaken to supply sunitinib to patients

with advanced RCC who might benefit from therapy, but who had no access to the drug prior to regulatory approval in their countries.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Sunitinib As First-Line Treatment For Metastatic Renal Cell Carcinoma (mRCC)
  • Pfizer Presents Overall Survival input For Sutent™ Versus Interferon-Alfa - First Treatment To Demonstrate Overall Survival Greater Than 2 Years
  • External Validation Of IMP3 Expression As An Independent Prognostic Marker For Metastatic Progression And Death For Patients With Renal Carcinona
  • Patients Given Sunitinib Need Close Monitoring For Cardiac Problems
  • Beyond The Abstract - Safety And Efficacy Of Mini-Margin Nephron-Sparing Surgery For Renal Cell Carcinoma 4-cm Or Less

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.